clinical trial · NCT07616934
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults
Group A Streptococcal InfectionPlaceboVAX-A1 LowVAX-A1 MidVAX-A1 High
brief summary
This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and immunogenicity of VAX-A1 in healthy adults 18-40 years of age.
started
Jun 1, 2026
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
Jun 16, 2026
official title
A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol